Skip to main content
. 2021 Mar 21;13:1759720X21999564. doi: 10.1177/1759720X21999564

Figure 3.

Figure 3.

Forest plots of network meta-analysis of all trials for efficacy and safety. A. ACR20. B. DAS28. C. HAQ-DI. D. Discontinuations for AEs. Drugs compared with placebo, which was the reference compound.

ACR20, American College of Rheumatology 20% response; AEs, adverse events; Crl, credible interval; csDMARDs, conventional synthetic disease-modifying antirheumatic drugs; DAS28, Disease Activity Score in 28 joints; HAQ-DI, Health Assessment Questionnaire–Disability Index; OR, odds ratio; WMD, weighted mean difference.